Contineum Therapeutics, Inc. (CTNM)

Market Cap	532.22M
Revenue (ttm)	50.00M
Net Income (ttm)	-447,000
Shares Out	25.72M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,016
Open	20.65
Previous Close	21.00
Day's Range	20.48 - 21.46
52-Week Range	13.27 - 22.00
Beta	n/a
Analysts	Strong Buy
Price Target	28.00 (+35.33%)
Earnings Date	Aug 16, 2024

About CTNM

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 5, 2024
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: CTNM

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 3 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 35.33% from the latest price.

Price Target

$28.0

(35.33% upside)

Analyst Consensus: Strong Buy